NanoViricides Inc. (NNVC)

[changes_iv]

Yes, EbolaCide II is bound to join the group of new drugs and vaccines to treat Ebola and possibly take the lead from Flucide in the race to FDA review/market (WHO review by November 2014). Thank you MDPH1.

Experts will be meeting this week at the World Health Organization (WHO) to discuss the role of new drugs and vaccines to help control the Ebola epidemic in West Africa. Last month, the WHO said that it is ethical to provide experimental drugs and vaccines for Ebola, but that there’s also a “moral duty” to conduct clinical trials of these experimental drugs and vaccines to determine whether they’re safe and effective. At the same time, a new study released last week shows that the Ebola virus is mutating rapidly, which could make it more transmissible or reduce the effectiveness of drugs and vaccines in the pipeline. ~ Reuters

Once we find (if we haven't already) and sign agreement with a partner (BSL-4 ViroLogics, USAMRIID, etc.) to test EbolaCide II, we could be done with Clinical Trials by the end of November. Why not? We are makers of low toxicity, efficacious and fast acting therapeutic drugs! As Ebola mutates the need for an alternative treatment to vaccines grows.

...vaccines usually fail with the emergence of mutated viruses. And when a person develops a disease, we still need to have a treatment ~ Dr. Anil Diwan, President of NanoViricides, Inc.

And nothing more credible to the masses than an unscientific description of the waters in which people are drowning, ..."...Ebola is mutating..." ~ community organizer in chief. Is his FDA going to first remove finding of the toxic dose (MFD) for FluCide and fast-track it? I mean really, why have a rerun of Ebola casualties but in the tens of thousands, for Influenza and MERS.

Perhaps we should all take a vote to have Zincy write a scientific letter to the FDA as to why we do not need to spend a month (or more) drowning rodents with low toxicity FluCide, to find the toxic dose. Or perhaps a Jedi monikered friend could convince the FDA, or the scientific DoJ, that we would like a democratic vote, instead of Clinical Trials, to take FluCide straight to market. Just like toxic Cannabis, we don't need Clinical Trials for low toxicity FluCide but a state by state democratic vote because the law/contracts can be honored or broken by the powerful in big government. Fired up, ready to go!

And just imagine how much faster your big "flat footed" government is going to move as deaths due to Influenza and/or MERS start piling up, splashed all over the evening news.

All we do is make the drug. The partners do the testing.

We will announce a partnership agreement when everything is signed.

There are very few BSL4 facilities in the world with whom we can work

I think that we explained in the PR why we feel that we can dramatically improve the efficacy with our new improved techniques.

We need a partner to try to get a piece of the available $100M EHO (sic WHO) grant.

This WILL NOT delay the start of the tox studies.

Sent from my iPhone

Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
[e-mail]
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange

Once we test EbolaCide II for efficacy and are successful, we should not be denied. The next step will be a fast track to WHO clinical trials to test for efficacy (again?) and safety!

We are stepping on Big Pharma toes...

There will always be a need and demand for vaccines, but many people won’t use them. We know this from experience. However, the existence of a nanoviricide treatment for a virus-borne illness means that treatment can begin after symptoms for influenza or some other virus-borne disease appear.

Based on animal studies, we believe that virus populations will be so reduced that symptoms would disappear in only a few hours. Immunity, however, would develop in the normal 21-day period so that the patient could not get the same infection again.

Some viruses—notably hepatitis, HIV, and herpes—might not be cleared entirely from the system because they hide inside various tissues. I believe, however, that symptoms will disappear, and the patient would not be contagious. When the virus emerges, however, it will encounter nanoviricides if they are in the patient’s system. Over time, there is a strong possibility that each reemergence will be smaller than the last, until the disease is gone.

http://www.mauldineconomics.com/download/transformational-wealth-from-three-tiny-companies

=========================================



In this lecture, tech investor Juan Enriquez explains how the FDA's extreme risk aversion hurts us, and why that behavior is our fault.